glp-1 for diabetes type 2 GLP1 Receptor Agonists vs SGLT2-I in Preventing CKD in T2DM: An Interview – AJKD Blog Dual GIP/GLP-1 receptor agonists: New

and GIP receptors have also been demonstrated to activate phosphoinositide 3-kinase (PI3K) and its downstream effector Akt, which modulates mitochondrial function, metabolism, and cell survival

gallbladder-related events which can occur with rapid weight loss

A new view of diabetic retinopathy: a neurodegenerative disease of the eye

Lower treatment burden While retatrutide shows significant promise, Eli Lilly is likely to disrupt the market more imminently and more substantially following the launch of orforglipron in early 2026

Holst, Wewer Albrechtsen, Gabe, Rosenkilde)

has received research grants (to his institution, Diabeteszentrum Bad Lauterberg) from AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., Merck Sharp & Dohme, Novartis Pharma, GlaxoSmithKline, Novo Nordisk, Roche, and Tolerx